Investigator

Eva Negri

Associate professor · University of Bologna, Department of Medical and Surgical Sciences (DIMEC)

ENEva Negri
Papers(4)
European trends in ov…Plant-Based Diets and…Fiber-type prebiotics…Hypertension and Risk…
Collaborators(10)
Carlo La VecchiaFederica TuratiGiovanna EspositoFabio ParazziniLuigino Dal MasoGrace GallagherGretchen L GierachHarvey RischHerbert YuImmaculata De Vivo
Institutions(7)
University Of BolognaUniversità degli Stud…Centro di Riferimento…Memorial Sloan Ketter…National Institutes o…Cuny Graduate School …University of Hawaii …

Papers

European trends in ovarian cancer mortality, 1990–2020 and predictions to 2025

Over the last decades, ovarian cancer mortality in Europe has been decreasing, but disparities in trends were observed. In this paper, we analysed ovarian cancer mortality trends in Europe over the period 1990-2020 and predicted the number of deaths and rates by 2025. We extracted population and death certification data from ovarian cancer in women for 31 European countries, between 1990 and 2020 from the World Health Organization database. We computed age-standardised mortality rates (ASMR) per 100,000 women-years, based on the world standard population. We also obtained predictions for 2025 using a joinpoint regression model and calculated the number of avoided deaths over the period 1994-2025. Over the observed period, mortality from ovarian cancer showed a favourable pattern in most countries. In the EU-27, rates declined by 5.9% from 2010-2014 to 2015-2019, reaching an ASMR of 4.66/100,000. During the same period, the decline in ovarian cancer mortality was more pronounced in the EU-14 countries (-7.0%) compared to Transitional countries (-2.1%). Declines were also observed in the United Kingdom, to reach an ASMR of 5.29. Decreases in mortality from ovarian cancer are predicted until 2025, to 4.17/100,000 for the EU-27. Favourable trends in ovarian cancer mortality are expected to persist in Europe and can be mainly attributed to the increased use of oral contraceptives in subsequent generations of European women. Decreased use of menopausal Hormone Replacement Therapy and improved diagnosis and management may also have played a role.

Plant-Based Diets and Ovarian Cancer Risk

Objective: To assess the relationship between adherence to various plant-based diets, as measured by overall, healthy, and unhealthy plant-based diet indices (PDI, hPDI, uPDI), and ovarian cancer risk. Methods: We obtained data on 1031 cases of ovarian cancer and 2411 controls from a case-control study conducted in Italy. PDI, hPDI, and uPDI were calculated using data from a validated food frequency questionnaire. We used logistic regression to calculate the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) of ovarian cancer for PDI, hPDI, and uPDI, adjusting for several possible confounders. Results: PDI and hPDI were inversely related to ovarian cancer risk (OR = 0.70 for the fourth compared to the first quartile, 95% CI: 0.55–0.89, and OR = 0.67, 95% CI: 0.53–0.84, respectively). On the other hand, a higher uPDI was related to a higher risk of ovarian cancer (OR = 1.78, 95% CI: 1.40–2.28). The estimates for a 5-point increment in the indices were 0.88 (95% CI: 0.81–0.95) for PDI, 0.90 (95% CI: 0.83–0.96) for hPDI, and 1.15 (95% CI: 1.07–1.23) for uPDI. Consistent associations for the three indices were observed across strata of age, family history of breast/ovarian cancer, educational level, parity, oral contraceptives use, and menopausal status. Conclusions: Plant-based diets favorably influence ovarian cancer risk; plant-based diets characterized by a high intake of unhealthy plant foods are linked to an increased risk. Promoting diets rich in healthy plant foods could support the reduction of ovarian cancer risk.

Fiber-type prebiotics and gynecological and breast cancers risk: the PrebiotiCa study

Abstract Prebiotics may influence the risk of hormone-related female cancers by modulating the gut microbiota involved in estrogen metabolism. We evaluated the association of fiber-type prebiotic intake with breast, endometrial, and ovarian cancers. Data derived from a network of Italian hospital-based case-control studies (1991-2006), including 2560 cases of cancer of the breast (n = 2588 control participants), 454 of the endometrium (n = 908 control participants), and 1031 of the ovary (n = 2411 control participants). Inulin-type fructans and selected fructo-oligosaccharides (namely, nystose, kestose, and 1F-β-fructofuranosylnystose) and galacto-oligosaccharides (namely, raffinose and stachyose) were quantified in food products via laboratory analyses. Prebiotic intake was estimated by multiplying intake according to food frequency questionnaire responses by the foods’ prebiotic content. Odds ratios (ORs) and the corresponding 95% CIs were derived by multiple logistic regression models. Nystose intake was marginally directly associated with breast (for quartile 4 vs quartile 1: OR = 1.20; 95% CI, 1.00-1.45), ovarian (OR = 1.39; 95% CI, 1.04-1.84), and endometrial (OR = 1.32; 95% CI, 0.85-2.03) cancer risk. High amounts of 1F-β-fructofuranosylnystose intake were inversely associated with ovarian cancer (OR = 0.67; 95% CI, 0.52-0.85). Inulin-type fructans, kestose, raffinose, and stachyose were not associated with the 3 cancers. The intake of most fiber-type prebiotics was not appreciably and consistently associated with breast, endometrial, and ovarian cancer risks. This article is part of a Special Collection on Gynecological Cancer.

Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)

Abstract Background: The incidence rates of endometrial cancer are increasing, which may partly be explained by the rising prevalence of obesity, an established risk factor for endometrial cancer. Hypertension, another component of metabolic syndrome, is also increasing in prevalence, and emerging evidence suggests that it may be associated with the development of certain cancers. The role of hypertension independent of other components of metabolic syndrome in the etiology of endometrial cancer remains unclear. In this study, we evaluated hypertension as an independent risk factor for endometrial cancer and whether this association is modified by other established risk factors. Methods: We included 15,631 endometrial cancer cases and 42,239 controls matched on age, race, and study-specific factors from 29 studies in the Epidemiology of Endometrial Cancer Consortium. We used multivariable unconditional logistic regression models to estimate ORs and 95% confidence intervals (CI) to evaluate the association between hypertension and endometrial cancer and whether this association differed by study design, race/ethnicity, body mass index, diabetes status, smoking status, or reproductive factors. Results: Hypertension was associated with an increased risk of endometrial cancer (OR, 1.14; 95% CI, 1.09–1.19). There was significant heterogeneity by study design (Phet < 0.01), with a stronger magnitude of association observed among case–control versus cohort studies. Stronger associations were also noted for pre-/perimenopausal women and never users of postmenopausal hormone therapy. Conclusions: Hypertension is associated with endometrial cancer risk independently from known risk factors. Future research should focus on biologic mechanisms underlying this association. Impact: This study provides evidence that hypertension may be an independent risk factor for endometrial cancer.

1172Works
4Papers
64Collaborators
Stomach NeoplasmsColorectal NeoplasmsNeoplasmsBreast NeoplasmsEndometrial NeoplasmsHelicobacter InfectionsOvarian NeoplasmsMouth Neoplasms

Positions

2021–

Associate professor

University of Bologna · Department of Medical and Surgical Sciences (DIMEC)

Links & IDs
0000-0001-9712-8526

Scopus: 55046538900